STX — Shield Therapeutics Share News
0.000.00%
Last trade - 00:00- £72.65m
- £86.55m
- $49.70m
REG - Shield Therapeutics - Q1 2026 Trading Update
AnnouncementREG - Shield Therapeutics - Total Voting Rights
AnnouncementREG - Shield Therapeutics - Enrollment in Phase II Clinical Trial for ACCRUFeR
AnnouncementREG - Shield Therapeutics - Audited results for year ended 31 December 2025
AnnouncementRCS - Shield Therapeutics - Publication of Report, Reinforcing FDA Approval
AnnouncementREG - Shield Therapeutics - Total Voting Rights
AnnouncementREG - Shield Therapeutics - EMA approves extension - to include adolescents
AnnouncementREG - Shield Therapeutics - Chinese NMPA Accepts MAA Submission for ACCRUFeR®
AnnouncementREG - Shield Therapeutics - Total Voting Rights
AnnouncementREG - Shield Therapeutics - FDA Grants additional Exclusivity for ACCRUFeR
AnnouncementREG - Shield Therapeutics - Total Voting Rights
AnnouncementREG - Shield Therapeutics - Approval for ACCRUFeR in China expected in Q1 2026
AnnouncementREG - Shield Therapeutics - Q4 2025 Trading Update
AnnouncementREG - Shield Therapeutics - Block listing 6 Monthly Return
AnnouncementREG - Shield Therapeutics - Total Voting Rights
AnnouncementREG - AIM - AIM Notice - 23/12/2025
AnnouncementREG - Shield Therapeutics - FDA approves extension for ACCRUFeR®
AnnouncementREG - Shield Therapeutics - Block Listing Application
AnnouncementRCS - Shield Therapeutics - Shield Wins Gold at Titan Branding Awards
Announcement